Evidence map›Paper›PMID 36567416›Full record

ReviewNeurotoxicity research2023

Therapeutic Molecular Insights into the Active Engagement of Cannabinoids in the Therapy of Parkinson's Disease: A Novel and Futuristic Approach.

Vaibhav Jain, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Hafiz A Makeen, Mohammed Albratty, Abdulkarim M Meraya, Asim Najmi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurotoxicity research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Vaibhav JainChitkara College of Pharmacy, Chitkara University, Punjab, India.
Tapan BehlSchool of Health Sciences, University of Petroleum and Energy Studies, Dehradun, Uttarakhand, India. tapanbehl31@gmail.com.
Aayush SehgalGHG Khalsa College of Pharmacy, Gurusar Sadhar, Ludhiana, Punjab, India.
Sukhbir SinghDepartment of Pharmaceutics, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to Be University), Mullana-Ambala, Ambala, 133207, Haryana, India.
Neelam SharmaDepartment of Pharmaceutics, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to Be University), Mullana-Ambala, Ambala, 133207, Haryana, India.
Hafiz A MakeenPharmacy Practice Research Unit, Clinical Pharmacy Department, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
Mohammed AlbrattyDepartment of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
Abdulkarim M MerayaPharmacy Practice Research Unit, Department of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
Asim NajmiDepartment of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
Jazan University · SAMaharishi Markandeshwar University, Mullana · INChitkara University · INUniversity of Petroleum and Energy Studies · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease is a neurodegenerative disorder which is characterised mostly by loss of dopaminergic nerve cells throughout the nigral area mainly as a consequence of oxidative stress. Muscle stiffness, disorganised bodily responses, disturbed sleep, weariness, amnesia, and voice impairment are all symptoms of dopaminergic neuron degeneration and existing symptomatic treatments are important to arrest additional neuronal death. Some cannabinoids have recently been demonstrated as robust antioxidants that might protect the nerve cells from degeneration even when cannabinoid receptors are not triggered. Cannabinoids are likely to have property to slow or presumably cease the steady deterioration of the brain's dopaminergic systems, a condition for which there is now no treatment. The use of cannabinoids in combination with currently available drugs has the potential to introduce a radically new paradigm for treatment of Parkinson's disease, making it immensely useful in the treatment of such a debilitating illness.

Indexed as

CannabinoidsNeurodegenerative DiseasesNeuroprotective AgentsParkinson DiseaseDopamineDopaminergic NeuronsHumansCannabinoidsDopamineNeuroprotective AgentsBasal gangliaCannabinoid receptorsCannabinoidsEndocannabinoids systemNeuroprotectionParkinson’s disease

Identifiers

PMID36567416
OpenAlexW4312142634

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.